Compare Brookfield Infrastructure Partners LP (BIP) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brookfield Infrastructure Partners LP vs Sana Biotechnology Inc — how do they compare? Brookfield Infrastructure Partners LP trades at $39.54 (market cap $18.10B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Brookfield Infrastructure Partners LP is far larger — about 16× Sana Biotechnology Inc's market cap, and Brookfield Infrastructure Partners LP pays a 4.62% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| BIP | SANA | |
|---|---|---|
Market Cap | $18.10B | $1.13B |
Sector | Industrials | Health |
52-Week High | $42.62 | $5.92 |
52-Week Low | $29.81 | $2.68 |
Enterprise Value | $77.05B | $1.05B |
Dividend Yield | 4.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Brookfield Infrastructure Partners (BIP) trades at $39.45, up 3.87% today, with a bullish technical signal from moving averages. The company reported revenue of $23.10B in 2025 but has missed recent EPS estimates, with Q2 2026 actual EPS at -$0.07 versus a $0.16 expectation. Recent news highlights its dividend appeal and corporate simplification plans, while analyst consensus remains strongly positive with a $44.67 price target.
BIP offers a high dividend yield and attractive EV/EBITDA valuation, but faces risks from earnings misses and high debt. The stock's upside depends on execution of its infrastructure strategy and improved profitability. Investor sentiment is buoyed by institutional support and media coverage emphasizing long-term value, though near-term volatility may persist amid macroeconomic uncertainty.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
